CNS cancer immunity cycle and strategies to target this for glioblastoma.

Ameratunga, Malaka; Coleman, Niamh; Welsh, Liam; Saran, Frank; Lopez, Juanita

Ameratunga, Malaka; Coleman, Niamh; Welsh, Liam; Saran, Frank; Lopez, Juanita.

Afiliación

Ameratunga M; Drug Development Unit, Royal Marsden Hospital and The Institute of Cancer Research, Sutton SM2 5PT, UK.
Coleman N; Drug Development Unit, Royal Marsden Hospital and The Institute of Cancer Research, Sutton SM2 5PT, UK.
Welsh L; Department of Neuro-Oncology, Royal Marsden Hospital and The Institute of Cancer Research, Sutton SM2 5PT, UK.
Saran F; Department of Neuro-Oncology, Royal Marsden Hospital and The Institute of Cancer Research, Sutton SM2 5PT, UK.
Lopez J; Drug Development Unit, Royal Marsden Hospital and The Institute of Cancer Research, Sutton SM2 5PT, UK.

Oncotarget ; 9(32): 22802-22816, 2018 Apr 27.

Article en En | MEDLINE | ID: mdl-29854316

Palabras clave

cancer-immunity cycle; checkpoint inhibitors; clinical trials; glioblastoma; immunotherapy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google